John M Burke, MD from Rocky Mountain Cancer Centers discusses monitor patients minimal residual disease status and maintenance doses of obinutuzumab & atezolizumab at the 2017 American Society of Hematology.
Monitor Patients Minimal Residual Disease Status – Maintenance doses of obinutuzumab & atezolizumab
